期刊
CELL REPORTS
卷 19, 期 4, 页码 746-759出版社
CELL PRESS
DOI: 10.1016/j.celrep.2017.04.004
关键词
-
类别
资金
- Ligue Nationale contre le Cancer
- Fondation de France
- Institut National du Cancer
- Association pour la Recherche sur le Cancer [PJA20131200160]
- Conseil Regional Bourgogne
- FEDER
- INSERM
- Fondation Lilliane Betancourt
- French National Research Agency [ANR-13-JSV3-0001, ANR-11-LABX-0021]
- Ligue Regionale contre le Cancer Comite Grand-Est
- Canceropole Grand-Est
- European Community (Marie Curie Fellowship) [PCIG10-GA-2011-303719]
- Agence Nationale de la Recherche (ANR) [ANR-13-JSV3-0001] Funding Source: Agence Nationale de la Recherche (ANR)
Sirtuin-1 deacetylates proteins and has emerged as a critical regulator of different cellular processes, particularly inflammation. Basal SIRT1 activity was previously found to limit Th9 and enhance Th17 differentiation in mice, but the effect of pharmacological SIRT1 activation on T cell differentiation and antitumor responses remains unclear. Here, we find that SIRT1 pharmacological agonists selectively impede mouse and human Th17 cell differentiation. SIRT1 activation induces STAT3 deacetylation, thus reducing its ability to translocate into the nucleus, bind to Rorc promoter, and induce its transcription. SIRT1 agonists reduce tumor growth in mice by blocking Th17 cell differentiation. In cancer patients, the SIRT1 agonist metformin reduced the frequency of Th17 cells and STAT3 acetylation levels. Altogether, these data underscore that SIRT1 activation impedes Th17 cell differentiation and thereby limits tumor growth and suggest that SIRT1 activators may directly target IL-17A functions.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据